Triptorelin a better bet for chemo-induced menorrhagia
- PDF / 123,530 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 78 Downloads / 167 Views
1
Triptorelin a better bet for chemoinduced menorrhagia Triptorelin is far more effective than medroxyprogesterone in preventing menorrhagia during episodes of chemotherapy-induced thrombocytopenia in female patients with cancer, according to researchers from Israel. They retrospectively identified 101 such patients (aged 12–51 years) with normal ovarial function and regular menstrual cycles who received high-dose or ablative chemotherapy and subsequently developed severe thrombocytopenia* during treatment; all patients received IM medroxyprogesterone [Depoprovera] 150mg every 3 months (n = 42), IM triptorelin [Decapeptyl] 3.75mg once a month (39) or no treatment prior to the initiation of chemotherapy. No difference was observed in the occurrence of moderate-to-severe nonvaginal general haemorrhage among patients who received triptorelin, medroxyprogesterone or no treatment. Overall, moderate and severe vaginal bleeding was observed in 17 (16.8%) patients, of whom 9 and 8 patients were in the medroxyprogesterone and untreated groups, respectively; none of the patients in the triptorelin group developed menorrhagia. The rate of menorrhagia was significantly lower for the treatment groups than the untreated group. A significant difference was observed between the groups in regard to the need for urgent gynaecologic consultation due to vaginal bleeding; 65% in the medroxyprogesterone group, 30.1% patients in the untreated group, and 3 patients in the triptorelin group required at least one gynaecologic consultation. No patients in the triptorelin group required conjugated estrogen treatment to stop severe menorrhagia, whereas 1.8% and 2.3% patients in the medroxyprogesterone and untreated groups, respectively, received conjugated estrogens. * platelet count < 25 000/µL Meirow D, et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 107: 1634-1641, No. 7, 1 801051748 Oct 2006
0114-9954/10/1126-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 4 Nov 2006 No. 1126
Data Loading...
